Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Quantifying the mechanism of transcranial magnetic stimulation in depression: A preliminary positron emission tomography study of microglia

Award Number: R21MH143131
ORGANIZATION: NATIONAL INSTITUTE OF MENTAL HEALTH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2026
PERIOD OF PERFORMANCE END DATE: 06/30/2028

Group Awards By:

View Award Description

Quantifying the mechanism of transcranial magnetic stimulation in depression: A preliminary positron emission tomography study of microglia - Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation methodology FDA- approved for treatment of major depressive disorder (MDD). While rTMS achieves higher antidepressant efficacy than conventional treatments, reported response and remission rates are highly variable across cohorts. To reduce this variability and enhance overall remission rates, an understanding of the biological mechanisms behind rTMS’s antidepressant efficacy is needed. Recent studies have identified that rTMS works through a common biological mechanism even across multiple neurological disorders being treated: reduction of neuroinflammation, specifically, reduction in microglia activation. This is particularly relevant for MDD, as increased neuroinflammation is well-documented, on average, in groups of patients with MDD, and microglia are reported to be the cells responsible for this neuroinflammation. We and others have shown that people with MDD exhibit a range of neuroinflammation and that only those with high neuroinflammation have an antidepressant response to anti-inflammatory treatment. Taken together, this suggests that the mechanism of action of rTMS may be through the reduction of neuroinflammation (specifically, microglia density) and that the reported heterogeneity in response to rTMS may be due to the heterogeneity of neuroinflammation in MDD itself. We seek to probe this in the proposed high-risk, high-reward proof-of-concept study in n = 10 treatment- seeking participants with MDD, who will undergo rTMS as part of their standard of care – this is not a clinical trial: Aim 1. Explore the relationship between rTMS-associated reductions in depression severity and reductions in microglial density, as measured by microglia-specific [11C]PS13 positron emission tomography (PET) tracer. We expect microglia density to decrease following rTMS based on published animal literature reporting a ~23% reduction in microglia after TMS. Data from our current study examining participants with MDD receiving anti-inflammatory medication suggest that reductions in depression severity will be correlated with this reduction in neuroinflammation. Aim 2. Explore the relationship between pretreatment microglia density as measured by [11C]PS13 PET and antidepressant response to rTMS. Data from our current study suggest that greater pretreatment neuroinflammation will be associated with better response to rTMS. This high-risk, high-reward R21 will be the first study to assess rTMS’s effects on microglia in patients with MDD, advancing our understanding of its mechanism of action, providing proof of concept to support future larger studies, and stimulating the development of both novel neuroinflammation-specific therapeutics and future improvements in rTMS protocols.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $437,125 )
2026	2026	THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK	W5510 FRANKS MELVILLE MEMORIAL LIBRARY	STONY BROOK	NY	11794	SUFFOLK	USA	Mental Health Research Grants	000	1	6/15/2026	NEW	$437,125
														Subtotal = $437,125

Grand Total All Awards = $437,125

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Quantifying the mechanism of transcranial magnetic stimulation in depression: A preliminary positron emission tomography study of microglia

Award Number: R21MH143131

ORGANIZATION: NATIONAL INSTITUTE OF MENTAL HEALTH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2026

PERIOD OF PERFORMANCE END DATE: 06/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer